Anti-Hemophilic Factor VIII Concentrate from Japan
A lyophilized concentrate of coagulation Factor VIII derived from human plasma, used therapeutically for hemophilia A treatment. Classified under HTS 3002.90.52 as an other blood fraction prepared for therapeutic uses via biotechnological purification. It replaces missing clotting factors in patients.
Duty Rate — Japan → United States
0%
Rate breakdown
9903.05.860%Articles provided for in subdivision (b) of U.S. note 52 to this subchapter
Import Tips
• Include lot-specific release certificates from FDA or equivalent for biologics import clearance
• Maintain ultra-low temperature shipping records (-80°C) to preserve potency during transit
• Beware of quota restrictions on plasma products; verify annual allocations with Customs